neomycin/polymyxin B/gramicidin ophthalmic (Gramicidin, Neosporin Ophthalmic Solution, Neocin-PG)
Classes: Antibiotics, Ophthalmic Combos
- Dosing and uses of Gramicidin, Neosporin Ophthalmic Solution (neomycin/polymyxin B/gramicidin ophthalmic)
- Gramicidin, Neosporin Ophthalmic Solution (neomycin/polymyxin B/gramicidin ophthalmic) adverse (side) effects
- Warnings
- Pregnancy
- Pharmacology of Gramicidin, Neosporin Ophthalmic Solution (neomycin/polymyxin B/gramicidin ophthalmic)
Dosing and uses of Gramicidin, Neosporin Ophthalmic Solution (neomycin/polymyxin B/gramicidin ophthalmic)
Adult dosage forms and strengths
ointment
- 3.5g
ophthalmic solution
- 10mL
Treatment & Prevention of Ocular Infection &/or Inflammation
Ointment: q3-4hr
Drops: 1-2 gtts q4hr for 7-10 days; if severe 2 gtts q1hr
Other Indications & Uses
Treatment of conjunctivitis of bacterial origin
Effective in combination with other topical agents for treatment of Acanthamoeba keratitis
Pediatric dosage forms and strengths
Same as adult dosing
Gramicidin, Neosporin Ophthalmic Solution (neomycin/polymyxin B/gramicidin ophthalmic) adverse (side) effects
Frequency not defined
Hypersensitivity
Itching, swelling, and conjunctival erythema
Local irritation
Allergic hypersensitivity
Anaphylaxis
Warnings
Contraindications
Aminglycoside/neomycin hypersensitivity; hypersensitivity to any component in product
Cautions
Watch for NEOMYCIN ocular sensitivity; drops contain gramacidin instead of bacitracin, since bacitracin not stable in solution
Combination of neomycin, polymixin and either gramacidin or bacitracin
Pregnancy and lactation
Pregnancy category: C
Lactation: safety in nursing infants unknown
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Gramicidin, Neosporin Ophthalmic Solution (neomycin/polymyxin B/gramicidin ophthalmic)
Mechanism of action
Inhibits bacterial cell wall synthesis by preventing the incorporation of amino acids and nucleotides into the cell walL
